Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: Results from a collaborative project of 11 European biologic registers

Annals of the Rheumatic Diseases

Volumn 76, Issue 2, 2017, Pages 386-391

  Mercer, Louise K ^a   Askling, Johan ^b,c   Raaschou, Pauline ^b   Dixon, William G ^a   Dreyer, Lene ^d,e   Hetland, Merete Lund ^f,g   Strangfeld, Anja ^h   Zink, Angela ^h,i   Mariette, Xavier ^j   Finckh, Axel ^k   Canhao, Helena ^l   Iannone, Florenzo ^m   Zavada, Jakub ^n,o   Morel, Jacques ^p   Gottenberg, Jacques Eric ^q   Hyrich, Kimme L ^a,r   Listing, Joachim ^h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f University of Copenhagen   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h German Rheumatism Research Centre   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITÉ PARIS SACLAY   (France)

^k UNIVERSITY OF GENEVA   (Switzerland)

^l UNIVERSITY OF LISBON   (Portugal)

^m UNIVERSITY OF BARI   (Italy)

ⁿ INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^o CHARLES UNIVERSITY   (Czech Republic)

^p LAPEYRONIE HOSPITAL   (France)

^q UNIVERSITÉ DE STRASBOURG   (France)

^r MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Anti TNF; Epidemiology; Rheumatoid Arthritis

Indexed keywords

ABATACEPT; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; POPULATION RESEARCH; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; EUROPE; INCIDENCE; MELANOMA; MIDDLE AGED; REGISTER; RISK FACTOR; SKIN NEOPLASMS; VERY ELDERLY;

ABATACEPT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; EUROPE; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; REGISTRIES; RISK FACTORS; RITUXIMAB; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978983306     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209285     Document Type: Article

References (26)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
2. Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013;132:385-400.
3. Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies. PLoS ONE 2014;9:e95096.
4. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
5. Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013;346:f1939.
6. Mercer LK, Davies R, Galloway JB, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013;52:91-8.
7. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
8. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9.
9. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
10. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
11. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
12. Dreyer L, Mellemkjaer L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013;72: 79-82.
13. Lazar-Molnar E, Hegyesi H, Toth S, et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-54.
14. Hofmann MA, Kiecker F, Küchler I, et al. Serum TNF-alpha, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-alpha2b treatment of patients with melanoma. J Cancer Res Clin Oncol 2011;137:455-62.
15. Liénard D, Eggermont AM, Kroon BB, et al. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 1998;14:202-9.
16. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
17. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
18. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
19. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904.
20. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
21. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74.
22. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011;50:222-9.
23. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
24. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
25. Hetland ML. DANBIO-powerful research database and electronic patient record. Rheumatology 2011;50:69-77.
26. Böhning D, Sarol J, Rattanasiri S, et al. A comparison of non-iterative and iterative estimators of heterogeneity variance for the standardized mortality ratio. Biostatistics 2004;5:61-74.